Serum SCC-Ag in Head and Neck Squamous Cell Carcinoma

Palermo, F.; Carniato, Antonella; Fede, Antonella; Boccaletto, Franco; Marchiori, Carlo

doi:10.1177/172460089000500303

Cited by 14 publications

(12 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, SCC had a moderate value in diagnosing NSCLC, since a elevated level of the marker was observed in patients with SQLC as well as those with other non-small cell cancer cell types [6][7][8][9][10]. However, it should be noted that the majority of these studies were performed 10-20 years ago [6][7][8][9][10]. In the last decade, CYFRA21-1, which was originally introduced as serum tumor marker for NSCLC [11][12][13], has gradually reduced the value of SCC in NSCLC management.…”

Section: Introductionmentioning

confidence: 98%

“…In patients with squamous cell lung cancer (SQLC), SCC levels were shown to be associated with the extent of disease [6][7][8][9][10]. Moreover, SCC had a moderate value in diagnosing NSCLC, since a elevated level of the marker was observed in patients with SQLC as well as those with other non-small cell cancer cell types [6][7][8][9][10]. However, it should be noted that the majority of these studies were performed 10-20 years ago [6][7][8][9][10].…”

Section: Introductionmentioning

confidence: 99%

“…Thereafter, SCC has proven to be a wellestablished tumor marker for squamous cell carcinoma from various organs [6,7]. In patients with squamous cell lung cancer (SQLC), SCC levels were shown to be associated with the extent of disease [6][7][8][9][10]. Moreover, SCC had a moderate value in diagnosing NSCLC, since a elevated level of the marker was observed in patients with SQLC as well as those with other non-small cell cancer cell types [6][7][8][9][10].…”

Section: Introductionmentioning

confidence: 99%

“…SCC is a subfraction of the tumor-associated antigen T-4 and was originally obtained from squamous cell carcinoma tissue from the uterine cervix [4,5]. Thereafter, SCC has proven to be a wellestablished tumor marker for squamous cell carcinoma from various organs [6,7]. In patients with squamous cell lung cancer (SQLC), SCC levels were shown to be associated with the extent of disease [6][7][8][9][10].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

A re-evaluation of squamous cell carcinoma antigen (SCC) as a serum marker for non-small cell lung cancer

et al. 2007

View full text Add to dashboard Cite

Squamous cell carcinoma antigen (SCC) is still a widely used tumor marker for monitoring non-small cell lung cancer (NSCLC), although recent reports discourage its routine use because of low sensitivity. This is a study evaluating the efficacy of SCC and CYFRA21-1 in diagnosing NSCLC. A chart review was performed in a university hospital in Japan, covering a period of 10 years, up to October 2004. During the study period, 142 (35.5%) among 400 NSCLC patients diagnosed, received serum assays of both SCC and CYFRA21-1. Elevated SCC and CYFRA21-1 levels were found in 29.6% and 59.2% of patients, respectively. SCC sensitivity was only 13.0% but CYFRA21-1 sensitivity rose to 73.9% in metastatic patients. The adjunct of SCC increased the CYFRA21-1 sensitivity by 6.3% in the overall population and by only 2.2% for patients with metastases. SCC determination should be considered an inefficient method as a potential diagnosing tool for NSCLC patients, and it provides no additional value when used in combination with CYFRA21-1.

show abstract

Section: Introductionmentioning

confidence: 98%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

A re-evaluation of squamous cell carcinoma antigen (SCC) as a serum marker for non-small cell lung cancer

et al. 2007

View full text Add to dashboard Cite

show abstract

“…There are several types of oral cancers, but around 90 % are squamous cell carcinomas, originating in the tissues that line the mouth and lips and cheek lining 2 . Epidemiological studies have shown that chewing of betel quid with tobacco; smoking is the major etiological factor of oral carcinogenesis in India 3 . The largest data on buccal mucosa cancers is from India and 70 % -80 % of the patients with buccal mucosa cancers are locally advanced at the time of presentation.…”

Section: Introductionmentioning

confidence: 99%

Molecular Docking and Bioavailability Studies of Caffeine and Caffeic Acid Compounds With Apoptosis Regulated Proteins

Nadanasabapathi¹,

Manju²

2014

J Biol Sci Opin

View full text Add to dashboard Cite

Oral squamous cell carcinoma is the most common type of oral cancer accounting for almost 90 % of all oral malignancies, around 20 % of cancer burden in India. Caffeine and caffeic acid widely present in many fruits, vegetables, coffee and these compounds having various proved pharmacological health benefits to human. In this study, we investigate the selected apoptotic regulated proteins (receptors) mutant p53, Bcl-2, Bax and casapase-9 from human origin, which is actively involving in oral cancer signaling. The receptors were docked to the caffeine and caffeic acid and the energy value obtained as follows using the Hex 6.0 docking software. These compounds have better bioavailability (ADME) and receptor and ligand interaction leads to involves in apoptosis signaling related to oral cancer.

show abstract

The role of squamous cell carcinoma antigen in the management of laryngeal and hypopharyngeal cancer

Lara

Cuyás

1995

Cancer

View full text Add to dashboard Cite

Background. The efficacy of squamous cell carcinoma antigen (SCC‐Ag) in laryngeal cancer to predict those patients who will relapse after primary treatment (surgery or radiotherapy) and its utility to detect relapses early and thereby increase salvage rates and cure were assesed. Methods. Sixty healthy donors and 168 patients with laryngeal cancer were included in this prospective trial. Squamous cell carcinoma antigen was measured at diagnosis in all patients, 24 hours and 1 week after surgery in 113 patients and every 10 Gy of administered dose and 2 weeks after treatment in 49 patients primarily referred to radiotherapy. The marker was determined every 3‐6 months during follow‐up. All patients who relapsed had SCC‐Ag studies before and after salvage treatment. Results. The selected cut‐off value was 1.5 ngr/ml (mean value in control group, 0.65 4+ 2 standard deviation [0.38]). Seventy‐eight percent of patients with cancer had elevated SCC‐Ag values at diagnosis. Squamous cell carcinoma antigen was statistically related to TNM categories (T, P < 0.04; N, P < 0.05; Stage, P < 0.01). Seventy‐five percent of those patients with previously elevated pretreatment values normalized after treatment. Incomplete surgical resection (P < 0.0001) or persistence of the disease after radiotherapy (P < 0.01) were related to high posttreatment values. Squamous cell carcinoma antigen was elevated in 88% of the patients who relapsed. In 55% of the recurrences, SCC‐Ag was elevated 3 months before pathologic confirmation of relapse. Salvage by surgery or radiotherapy was effective in 70% of the patients. Squamous cell carcinoma antigen posttreatment values were the most important factor in predicting disease free survival (DFS) (P < 0.0001) and overall survival (P < 0.03). Conclusions. Squamous cell carcinoma antigen is an excellent marker of residual disease after primary treatment that can lead to the addition of other therapeutic procedures (surgery and postoperative radiotherapy). The absence of posttreatment SCC‐Ag is the best predictor of DFS, its presence detects recurrence in early stages, permitting salvage of an increased proportion of patients primarily referred for palliative treatment.

show abstract

Serum SCC-Ag in Head and Neck Squamous Cell Carcinoma

Cited by 14 publications

References 5 publications

A re-evaluation of squamous cell carcinoma antigen (SCC) as a serum marker for non-small cell lung cancer

A re-evaluation of squamous cell carcinoma antigen (SCC) as a serum marker for non-small cell lung cancer

Molecular Docking and Bioavailability Studies of Caffeine and Caffeic Acid Compounds With Apoptosis Regulated Proteins

The role of squamous cell carcinoma antigen in the management of laryngeal and hypopharyngeal cancer

Contact Info

Product

Resources

About